Skip to main content
evidena care

Safety

Cannabis medicine despite a pre-existing mental illness?

You have had depression, or there was a psychosis in your family: is a cannabis medicine an option?

Cannabis medicine despite a pre-existing mental illness?

Key points

  • According to the specialist society SGCM, a cannabis medicine is completely ruled out only in the case of an allergy to its ingredients. With severe psychiatric illnesses, your doctor examines therapy with THC strictly.
  • For a ready-made cannabis medicine authorised in Switzerland, psychosis in the family is a contraindication. The SGCM does not mention it specifically, so raise it in the conversation.
  • Report changes in mood, thinking or perception during therapy promptly; in an acute emergency, call 144.

You have had depression, or there was a psychosis in your family: is a cannabis medicine an option? A pre-existing mental illness does not automatically rule it out. With severe psychiatric illnesses, the specialist society SGCM requires a strict assessment for THC. In research, schizophrenia in a father or mother is considered a risk factor for developing a psychosis yourself.1,10

What matters is that your doctor knows your full history. So also tell them about earlier illnesses, not just current ones. Anyone who says nothing about it for fear of a no removes the basis of the assessment.

With psychosis and panic attacks, the assessment is strict

The SGCM distinguishes two levels. A cannabis medicine is completely ruled out only in the case of an allergy or hypersensitivity to cannabis, THC, CBD or excipients. For THC, it additionally requires a “strict indication” in serious psychiatric illnesses, above all psychoses and panic attacks, explicitly also in the medical history, that is, even if the illness existed in the past. This means: your doctor weighs benefits and risks particularly carefully before a prescription is issued. The SGCM provides for the same in the case of a current or past addiction.1

The product information of a ready-made cannabis medicine authorised in Switzerland puts it more strictly. It rules out use if schizophrenia or another psychosis is known or suspected in your own history or in the family. The same applies to suicidal thoughts, severe personality disorders and other significant psychiatric disorders, except depression resulting from the underlying condition. This list belongs to that preparation. If another cannabis medicine contains THC, your doctor includes the known risks of THC in the assessment just the same.1,3

The SGCM does not mention bipolar disorder specifically. In people with bipolar disorder, cannabis use was associated in several studies with a worsening of manic symptoms. The researchers themselves consider their conclusions provisional.1,8

Depression or anxiety: what counts is how severe the illness is

With a serious depression or anxiety disorder, the strict assessment may also apply, even though the SGCM does not name these illnesses individually. Whether a past or current depression or anxiety disorder counts is assessed by whoever prescribes the medicine. According to the FOPH, responsibility for treatment lies exclusively with the doctors.1,2

If you already take psychotropic medicines, do not stop them on your own, but discuss every change with your doctor.

However, depression is also on the list of possible side effects of THC; see the warning signs further below. After an earlier depression, it is therefore worth consciously observing your mood during therapy. Which interactions with antidepressants and other medicines are known is explained in the articles Cannabis and antidepressants and Interactions with medicines.1

Psychosis in the family: what the predisposition means

In the case of psychosis in the family, the product information of the ready-made medicine mentioned rules out use. The SGCM does not mention the family predisposition specifically. So raise it in the first conversation.1,3

In a Danish register of 2.28 million people, which records treatments rather than use, children of a mother with schizophrenia had a roughly five times higher risk of an illness in the schizophrenia spectrum. The risk of a cannabis-induced psychosis was roughly 2.5 times higher. Only people in treatment were recorded, and the diagnosis of a cannabis-related psychosis is considered uncertain.9

A Swiss specialist review on early detection counts children of parents with schizophrenia among the group at increased risk of psychosis and names cannabis use as a possible risk factor in the period before a psychosis. An increased risk, however, does not necessarily mean that you yourself will become ill.10

Pre-existing mental illness: how to prepare for the assessment

The SGCM does not recommend cannabis medicines as a first treatment. Use is considered an individual therapy attempt if the usual treatment does not work or is not tolerated. Since 1 August 2022, doctors can prescribe them without authorisation from the FOPH, and the FOPH does not name a specific specialty for this.1,2

This list helps for the first conversation:

  • Your own diagnoses: past and current mental illnesses with an approximate date, including single episodes.
  • Family: psychoses, schizophrenia or bipolar disorder in parents, siblings or children.
  • Addiction: a current or past dependence, including on alcohol or medicines.
  • Medicines: all medicines you currently take, with the dose, including sleeping pills and sedatives.
  • Treating professional: name and contact details of your psychiatrist or psychotherapist, if you are in treatment.
  • Reports: existing medical reports or hospital discharge reports.

If you are in psychiatric treatment, ask whether the prescribing doctor will coordinate with your psychiatrist. If you are advised against a cannabis medicine, ask for the reason to be explained and discuss with your treating professional which other treatments are an option.

Warning signs during therapy and what you do then

Among the possible side effects of THC, the SGCM also lists some that affect the mind: unusual elation or irritable low mood, disturbances of thinking or speech, psychosis, delusions and depression. If undesirable effects occur, your doctor assesses case by case whether the dose stays the same, is reduced or the therapy ends.1

Report such changes promptly, not only at the next appointment. Ask someone you trust to tell you if they notice anything about you. For the ready-made medicine mentioned, the product information requires treatment to be stopped immediately in the event of a psychotic reaction and the person to be closely monitored. Further possible side effects are described in the article Side effects of cannabis.3

In an acute emergency, call the medical emergency number 144. For a conversation in a crisis, adults can reach Die Dargebotene Hand by telephone on 143 around the clock, anonymously and confidentially; chat and e-mail are also available. Children and young people can reach Pro Juventute on 147, and there are also cantonal crisis numbers.11,12

Cannabis and psychosis: association is not the same as cause

Psychoses are multifactorial illnesses. There is no single cause: genetic predisposition, environmental factors, psychosocial stress and various noxae, that is, harmful influences such as certain substances, act together. Exactly how a psychosis develops is still not fully understood. In this picture, cannabis is one possible factor among several.13

Just as important is the difference between correlation and causation. Epidemiologically, there is an association between cannabis and psychoses, above all with early, frequent and high-potency use. In a European study with 901 people with a first psychosis and 1,237 controls, people with daily use had roughly 3.2 times higher odds of a psychosis than people without use. With daily use of cannabis with at least 10% THC, the odds were roughly 4.8 times higher.7,14

An observed association alone, however, does not prove a cause. It is also conceivable that shared factors such as a genetic predisposition make both more likely, or that people in an early phase of the illness are more likely to turn to cannabis. A causal role of cannabis is discussed scientifically and supported by various findings, for example by the fact that the risk increases with the amount used and that THC can temporarily trigger psychotic symptoms in healthy volunteers. For the individual person, however, it cannot be determined unambiguously whether cannabis contributed to a psychosis.6,7,13

What the research does not say

A 2026 review in the journal Lancet Psychiatry summarised randomised trials in which cannabinoids were tested as the main treatment of mental illnesses and addictions. For anxiety disorders, psychotic disorders and post-traumatic stress disorder, it found no proven benefit. There was no such trial on depression, and too little data on bipolar disorder.5

Undesirable effects were more frequent overall with cannabinoids, serious adverse events were not. Many trials had a high risk of bias, and the certainty of the results was mostly low. The authors consider routine use in these illnesses rarely justified at present.5

For your question, one limit matters above all: the figures on cannabis and psychosis in this article come from studies of recreational use or of healthy volunteers, not from medically supervised therapy. In an analysis of ten studies with 66,816 people, those with the heaviest use had roughly 3.9 times the odds of a psychosis compared with people without use. The more use, the higher the odds; whether cannabis is the cause could not be clarified unambiguously. In healthy volunteers, a single dose of THC triggered psychotic symptoms. Whether CBD triggers such symptoms or weakens the effect of THC is not shown consistently by the four studies on this.6,7

The 2026 review tested cannabinoids as a treatment of the mental illness itself. It says nothing directly about people who receive a cannabis medicine for other complaints and have a pre-existing mental illness. The FOPH also writes that sufficient clinical data are lacking for most uses.4,5

How it works at evidena

You arrange the first appointment in the portal at https://portal.evidena.care/appointments; if you are already in treatment, book a further consultation at https://portal.evidena.care/appointments/new. Have the contact details of your psychiatrist and the reports from the list above ready for the consultation. If a prescription is issued, it must be filled at a pharmacy within one month. As a rule, the prescribed quantity covers one month, in justified cases at most three months of treatment.15 If you notice a change during therapy, promptly inform the doctor who issued the prescription and your GP practice or your psychiatrist. If there are clear changes, do not wait for an appointment, but contact the medical emergency service. In an acute emergency, the emergency numbers above apply.

Conclusion

Put together the list above in advance and bring it to the first conversation, including single earlier episodes. How the assessment works at evidena is described on the page Cannabis therapy at evidena.

Frequently asked questions

Can cannabis trigger a psychosis?

It is possible: the SGCM lists psychosis among the possible side effects of THC. In studies on recreational use, heavy use was associated with a higher risk of psychosis; whether cannabis is the cause remained open.

Cannabis and psychosis: what to do if there are warning signs?

Contact the doctor who prescribed it promptly. If there are clear changes, contact the medical emergency service, in an acute emergency the emergency number 144, and for a conversation in a crisis 143.

Who may prescribe a cannabis medicine?

Doctors, since 1 August 2022 without authorisation from the FOPH. The FOPH does not name a specific specialty for this, and a psychiatrist can also prescribe. Responsibility lies with the person who prescribes.

Does psychosis in the family mean that I will not get a cannabis medicine?

For the ready-made medicine mentioned above, the product information rules out use in this case. The SGCM does not mention the predisposition specifically, which is why it belongs in the conversation with your doctor.

Your situation is individual

Discuss your questions with a doctor.

Book a consultation

Sources

  1. Allgemeine Informationen zur Anwendung von Medizinalcannabis für Fachpersonen (Fachinformation), Schweizerische Gesellschaft für Cannabis in der Medizin SGCM, ohne Datum (Dateipfad 2024/06), S. 4, 6 und 9 (accessed 21 October 2026)
  2. Gesetzesänderung Cannabisarzneimittel, Bundesamt für Gesundheit BAG, ohne Datum (accessed 21 October 2026)
  3. Fachinformation eines zugelassenen Cannabis-Fertigarzneimittels, Swissmedicinfo, Stand April 2023 (accessed 21 October 2026)
  4. Behandlungsempfehlungen für den Einsatz von Cannabisarzneimitteln, Bundesamt für Gesundheit BAG, 17. Januar 2025 (accessed 21 October 2026)
  5. Wilson J et al., systematische Übersicht und Metaanalyse randomisierter Studien zu Cannabinoiden bei psychischen Erkrankungen und Suchterkrankungen, Lancet Psychiatry 2026;13(4):304-315, PMID 41856154, DOI 10.1016/S2215-0366(26)00015-5; Erratum: Lancet Psychiatry 2026;13(8):e11, PMID 42302809
  6. Hindley G et al., Metaanalyse zu psychiatrischen Symptomen nach THC- und CBD-Gabe bei gesunden Freiwilligen, Lancet Psychiatry 2020. DOI 10.1016/S2215-0366(20)30074-2
  7. Marconi A et al., Metaanalyse zu Konsummenge und Psychoserisiko, Schizophrenia Bulletin 2016. DOI 10.1093/schbul/sbw003
  8. Gibbs M et al., systematische Übersicht zu Cannabiskonsum und manischen Symptomen bei bipolarer Störung, Journal of Affective Disorders 2015. DOI 10.1016/j.jad.2014.09.016
  9. Arendt M et al., dänische Registerstudie zu familiärer Belastung und cannabisinduzierter Psychose, Archives of General Psychiatry 2008. DOI 10.1001/archpsyc.65.11.1269
  10. Michel C, Kasteler M, Flückiger R, Früherkennung und -intervention von Psychosen bei Kindern, Jugendlichen und jungen Erwachsenen, Schweizer Zeitschrift für Psychiatrie und Neurologie 2/2020 (accessed 21 October 2026)
  11. Psychiatrische Notfälle Schweiz, Universitäre Psychiatrische Dienste Bern, ohne Datum (accessed 21 October 2026)
  12. Die Dargebotene Hand, Telefon 143 (accessed 21 October 2026)
  13. Jauhar S, Johnstone M, McKenna PJ, Übersichtsarbeit zur Schizophrenie (Ursachen, Genetik, Umweltfaktoren, Debatte um Cannabis), Lancet 2022;399(10323):473-486. DOI 10.1016/S0140-6736(21)01730-X
  14. Di Forti M et al., europäische Fall-Kontroll-Studie (EU-GEI) zu Konsummuster, THC-Gehalt und Psychoserisiko, Lancet Psychiatry 2019;6(5):427-436. DOI 10.1016/S2215-0366(19)30048-3
  15. Betäubungsmittelkontrollverordnung (BetmKV), SR 812.121.1, Art. 47, Stand am 23. Januar 2023, Fedlex (accessed 13 November 2026)

Written by evidena.care editorial team · Published 28 October 2026 · Reviewed 13 November 2026

This article is general information and does not replace medical advice. Whether cannabis therapy is an option for you is decided by a doctor in a personal consultation.